Physician profile
Heather A Smith
NPI 1487600540
$2,251.84
in general payments reported to CMS, 2019-2025
13 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $586 · 2023: $303 · 2024: $355 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.72 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.47 | 2021-2023 | |
| Astellas Pharma US INC | $379.94 | 2022-2025 | |
| Incyte Corporation | $221.51 | 2022-2025 | Jakafi |
| Stemline Therapeutics INC. | $152.64 | 2023-2024 | Elzonris |
| Rigel Pharmaceuticals, INC. | $133.94 | 2024 | Tavalisse, Rezlidhia |
| Otsuka America Pharmaceutical, INC. | $120.83 | 2024 | Rexulti |
| Seagen INC. | $103.60 | 2021 | |
| Genmab U.S., INC. | $47.60 | 2024 | Epkinly |
| Astellas Pharma Global Development | $42.56 | 2021-2023 | Xospata |
| Pharmacyclics LLC, An Abbvie Company | $25.26 | 2023 | Imbruvica |
| Abbott Laboratories | $23.91 | 2023 | I-Stat |
| Genentech USA, INC. | $19.61 | 2022 | |
| Daiichi Sankyo INC. | $18.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.